Yki-Järvinen H
Department of Medicine, University of Helsinki, Finland.
Drugs. 2000 Nov;60(5):975-83. doi: 10.2165/00003495-200060050-00001.
Although the diagnosis of type 2 (noninsulin-dependent) diabetes mellitus is made when blood glucose levels exceed values which increase the risk of microvascular complications, macrovascular disease is the major complication of type 2 diabetes mellitus. Both epidemiological and prospective data have demonstrated that treatment of hyperglycaemia is markedly effective in reducing the risk of microvascular disease but is less potent in reducing that of myocardial infarction, stroke and peripheral vascular disease. Treatment of other cardiovascular risk factors, although by definition less prevalent than hyperglycaemia, appears to be more effective in preventing macrovascular disease than treatment of hyperglycaemia. In recent years, data from intervention trials have suggested that greater benefits with respect to the prevention of macrovascular disease can be achieved by effective treatment of hypertension and hypercholesterolaemia, and by the use of small doses of aspirin (acetylsalicylic acid) than by treating hyperglycaemia alone. On the other hand, the UK Prospective Diabetes Study (UKPDS), which examined the impact of intensive glucose and blood pressure (BP) control on micro- and macrovascular complications, is the only intervention trial to include only patients with type 2 diabetes mellitus. The UKPDS data, the epidemic increase in the number of patients with type 2 diabetes mellitus and their high cardiovascular risk have, however, initiated several new trials addressing, in particular, the possible benefits of treatment of the most common form of dyslipidaemia (high serum triglyceride and low high density lipoprotein cholesterol levels) in these patients. Type 2 diabetes mellitus is thus a disease associated with a high vascular risk, where the majority of patients need, and are likely to benefit from, pharmacological treatment of several cardiovascular risk factors provided treatment targets have not been achieved by life-style modification.
尽管当血糖水平超过增加微血管并发症风险的值时即可诊断为2型(非胰岛素依赖型)糖尿病,但大血管疾病却是2型糖尿病的主要并发症。流行病学数据和前瞻性数据均已表明,治疗高血糖对降低微血管疾病风险具有显著效果,但在降低心肌梗死、中风和外周血管疾病风险方面效果较差。治疗其他心血管危险因素,虽然从定义上讲不如高血糖普遍,但在预防大血管疾病方面似乎比治疗高血糖更有效。近年来,干预试验的数据表明,与单独治疗高血糖相比,有效治疗高血压和高胆固醇血症以及使用小剂量阿司匹林(乙酰水杨酸)在预防大血管疾病方面能带来更大益处。另一方面,英国前瞻性糖尿病研究(UKPDS)考察了强化血糖和血压控制对微血管和大血管并发症的影响,这是唯一一项仅纳入2型糖尿病患者的干预试验。然而,UKPDS的数据、2型糖尿病患者数量的流行增加及其高心血管风险引发了几项新的试验,尤其针对治疗这些患者中最常见的血脂异常形式(高血清甘油三酯和低高密度脂蛋白胆固醇水平)可能带来的益处。因此,2型糖尿病是一种血管风险高的疾病,在这种疾病中,大多数患者如果通过生活方式改变未能实现治疗目标,就需要并可能从对多种心血管危险因素的药物治疗中获益。